NO329769B1 - Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander - Google Patents

Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander Download PDF

Info

Publication number
NO329769B1
NO329769B1 NO20000396A NO20000396A NO329769B1 NO 329769 B1 NO329769 B1 NO 329769B1 NO 20000396 A NO20000396 A NO 20000396A NO 20000396 A NO20000396 A NO 20000396A NO 329769 B1 NO329769 B1 NO 329769B1
Authority
NO
Norway
Prior art keywords
abzyme
plaques
fragment
api
peptide
Prior art date
Application number
NO20000396A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000396L (no
NO20000396D0 (no
Inventor
Sergio Rosini
Silvia Trasciatti
Original Assignee
Abiogen Pharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma Spa filed Critical Abiogen Pharma Spa
Publication of NO20000396D0 publication Critical patent/NO20000396D0/no
Publication of NO20000396L publication Critical patent/NO20000396L/no
Publication of NO329769B1 publication Critical patent/NO329769B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO20000396A 1997-07-30 2000-01-26 Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander NO329769B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001826A IT1293511B1 (it) 1997-07-30 1997-07-30 Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
PCT/EP1998/004706 WO1999006066A2 (en) 1997-07-30 1998-07-28 Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions

Publications (3)

Publication Number Publication Date
NO20000396D0 NO20000396D0 (no) 2000-01-26
NO20000396L NO20000396L (no) 2000-03-29
NO329769B1 true NO329769B1 (no) 2010-12-13

Family

ID=11377678

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000396A NO329769B1 (no) 1997-07-30 2000-01-26 Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander

Country Status (17)

Country Link
US (1) US6387674B1 (de)
EP (1) EP0996463B1 (de)
JP (1) JP2001511369A (de)
CN (1) CN1268175A (de)
AT (1) ATE466883T1 (de)
AU (1) AU741368B2 (de)
CA (1) CA2299442C (de)
CY (1) CY1110128T1 (de)
DE (1) DE69841653D1 (de)
DK (1) DK0996463T3 (de)
ES (1) ES2340892T3 (de)
IL (1) IL134142A0 (de)
IT (1) IT1293511B1 (de)
NO (1) NO329769B1 (de)
NZ (1) NZ502527A (de)
PT (1) PT996463E (de)
WO (1) WO1999006066A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6613505B2 (en) 2001-04-12 2003-09-02 Bioresource International, Inc. Composition and method for destruction of infetious prion proteins
EP2165714B1 (de) 2001-04-30 2013-10-23 Eli Lilly And Company Humanisierte Antikörper die das Beta-Amyloid Peptid erkennen
EP1385544B1 (de) 2001-04-30 2008-09-24 Eli Lilly And Company Humanisierte antikörper
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (de) * 2005-12-12 2008-08-27 AC Immune S.A. Monoklonaler antikörper
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (de) * 2006-07-14 2014-02-19 AC Immune S.A. Humanisierter antikörper gegen amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK2121754T3 (en) 2007-01-18 2015-02-23 Lilly Co Eli Pegylated amyloid BETA FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
US8454547B2 (en) * 2009-02-25 2013-06-04 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
US8317737B2 (en) * 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8246565B2 (en) * 2009-02-25 2012-08-21 The Invention Science Fund I, Llc Device for passively removing a target component from blood or lymph of a vertebrate subject
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
EP2825553B1 (de) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispezifische antigenbindungsmoleküle und verwendungen davon
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US6156541A (en) * 1995-07-21 2000-12-05 The Board Of Regents Of The University Of Nebraska Compositions and methods for catalyzing hydrolysis of HIV gp120

Also Published As

Publication number Publication date
CY1110128T1 (el) 2015-01-14
CA2299442C (en) 2011-06-21
IL134142A0 (en) 2001-04-30
ITMI971826A1 (it) 1999-01-30
ATE466883T1 (de) 2010-05-15
AU741368B2 (en) 2001-11-29
CA2299442A1 (en) 1999-02-11
IT1293511B1 (it) 1999-03-01
JP2001511369A (ja) 2001-08-14
WO1999006066A3 (en) 1999-04-29
NO20000396L (no) 2000-03-29
CN1268175A (zh) 2000-09-27
DK0996463T3 (da) 2010-08-09
NO20000396D0 (no) 2000-01-26
AU9255398A (en) 1999-02-22
EP0996463B1 (de) 2010-05-05
PT996463E (pt) 2010-05-17
WO1999006066A2 (en) 1999-02-11
ES2340892T3 (es) 2010-06-10
DE69841653D1 (de) 2010-06-17
NZ502527A (en) 2003-01-31
EP0996463A2 (de) 2000-05-03
US6387674B1 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
NO329769B1 (no) Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander
EP1781703B1 (de) Gegen lösliche amyloid-beta-peptid-protofibrile spezifische antikörper und deren verwendungen
US20110250211A1 (en) Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US11104710B2 (en) Methods and compositions comprising tau oligomers
US20210395319A1 (en) Methods and compositions comprising tau oligomers
JPWO2006016644A1 (ja) 抗体及びその利用
Pastorino et al. Alzheimer's disease-related loss of Pin1 function influences the intracellular localization and the processing of AβPP
KR20110031989A (ko) 진단용 항체 검사법
CN107708733A (zh) 抗分拣蛋白抗体和其使用方法
EA038120B1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
WO2008051326A2 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
Hesse et al. sAPPβ and sAPPα increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Ca2+ homeostasis and CREB1-signaling
MXPA00001109A (en) Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions
HK1029604A (en) Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions
Ager et al. Stem Cell Therapy for Alzheimer’s Disease
Meli Intracellularly selected recombinant antibodies targeting β Amyloid Oligomers
류승현 SCAMP5/AP-4 dependent trafficking mediates presynaptic localization of the core autophagy protein ATG9A
Podpolny The role of DKK3 in synapse dynamics in the adult hippocampus and in Alzheimer’s Disease
Jessen Characterization of the protein phosphatase 1E (PPM1E): localisation and truncation in brain tissue and effects on neuronal morphology in primary neuronal culture
Díaz-Hung et al. Beta Amyloid Peptides: Extracellular and Intracellular
Brady Investigating Mechanisms Of Ftld-Tdp Pathogenesis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees